DCM
CGEM icon

Dupont Capital Management’s Cullinan Oncology CGEM Stock Holding History

Dupont Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,348
Closed -$145K – 1556
2022
Q2 		$145K Hold
11,348
– – 0.01% 1079
2022
Q1 		$119K Buy
+11,348
New +$153K ﹤0.01% 1220

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dupont Capital Management's CGEM Position: Q3 2022 in Review

Dupont Capital Management sold out of Cullinan Oncology (CGEM) in Q3 2022, closing a stake of 11,348 shares — an estimated $145K sold.

Dupont Capital Management first reported a position in CGEM in Q1 2022 and held it in 2 quarters. The position peaked at $145K in Q2 2022. 99 funds tracked by Wall St. Rank hold CGEM as of Q3 2022.

  • Dupont Capital Management reported no remaining Cullinan Oncology position as of Q3 2022 after selling out during the quarter.
  • Dupont Capital Management sold 11,348 Cullinan Oncology shares in Q3 2022, an estimated $145K.
  • Dupont Capital Management first reported a position in Cullinan Oncology in Q1 2022 and held it in 2 quarters.
  • Dupont Capital Management's Cullinan Oncology position peaked at $145K in Q2 2022.
  • 99 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.